Rew D A
Department of Surgery, University of Leicester, Glenfield Hospital, UK.
Postgrad Med J. 1998 Feb;74(868):77-88. doi: 10.1136/pgmj.74.868.77.
Surgery remains the mainstay of treatment for most classes of human solid tumours, with the principal exception of lymphomas, but it is insufficient in many cases to guarantee cure. With few exceptions, recurrent and metastatic solid tumours continue to defy attempts to develop effective adjuvant therapies. Recent insights into tumour biology reveal an increasingly complex picture of cell and molecular processes which confer heterogeneity and resistance to treatment upon tumours. These insights may also yield new targets for more effective adjuvant therapies.
手术仍然是大多数人类实体瘤治疗的主要手段，淋巴瘤是主要的例外情况，但在许多情况下，手术不足以确保治愈。除了少数例外，复发性和转移性实体瘤仍然难以开发有效的辅助治疗方法。最近对肿瘤生物学的深入了解揭示了细胞和分子过程越来越复杂的情况，这些过程赋予肿瘤异质性和抗药性。这些见解也可能为更有效的辅助治疗带来新的靶点。
